Abstract
A retrospective study on 25 women (8 with endometrial carcinoma, 17 with severe endometrial atypical hyperplasia) under 35 years treated with progestin showed that six cases (75%) in the endometrial carcinoma (EC) group and 17 (100%) in the atypical hyperplasia (AH) group responded to the treatment, and among the 14 complete responders, 4 (40%) patients with AH had 7 pregnancies and 3 healthy deliveries. Given accurate pretreatment assessment, progestin therapy is a feasible management option to preserve fertility for young women with well-differentiated endometrial carcinoma or severe atypical hyperplasia of endometrium.
MeSH terms
-
17 alpha-Hydroxyprogesterone Caproate
-
Adult
-
Antineoplastic Agents, Hormonal / administration & dosage*
-
Cell Differentiation
-
Combined Modality Therapy
-
Endometrial Neoplasms / drug therapy*
-
Endometrial Neoplasms / pathology
-
Endometrium / drug effects
-
Endometrium / pathology
-
Female
-
Fertility*
-
Follow-Up Studies
-
Humans
-
Hydroxyprogesterones / administration & dosage
-
Hyperplasia
-
Infertility, Female / prevention & control*
-
Medroxyprogesterone Acetate / administration & dosage*
-
Megestrol Acetate / administration & dosage
-
Progestins / administration & dosage
-
Remission Induction
-
Reproductive Techniques, Assisted
-
Retrospective Studies
-
Severity of Illness Index
Substances
-
Antineoplastic Agents, Hormonal
-
Hydroxyprogesterones
-
Progestins
-
17 alpha-Hydroxyprogesterone Caproate
-
Medroxyprogesterone Acetate
-
Megestrol Acetate